T1	PROC 46 61	Estudio clínico
#1	AnnotatorNotes T1	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T2	CHEM 75 86	flucitosina
#2	AnnotatorNotes T2	C0016278; flucytosine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T3	DISO 104 140	carcinoma avanzado de tubo digestivo
T4	ANAT 126 140	tubo digestivo
#3	AnnotatorNotes T4	C0017189; Gastrointestinal tract structure; Body System | C4516948; Entire digestive tract; Body System
T5	PROC 163 184	Estudio de fase I/IIa
T6	PROC 233 256	infusiones intravenosas
#4	AnnotatorNotes T6	C0021440; Intravenous infusion procedures; Therapeutic or Preventive Procedure
T7	ANAT 410 426	gastrointestinal
#5	AnnotatorNotes T7	C0012240; Gastrointestinal system; Body System
T8	CHEM 283 294	flucitosina
#6	AnnotatorNotes T8	C0016278; flucytosine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T9	CHEM 301 317	5 fluorocitosina
#7	AnnotatorNotes T9	C0016278; flucytosine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T10	DISO 342 378	carcinoma avanzado de tubo digestivo
T11	ANAT 364 378	tubo digestivo
#8	AnnotatorNotes T11	C0017189; Gastrointestinal tract structure; Body System | C4516948; Entire digestive tract; Body System
T12	DISO 403 426	Cáncer gastrointestinal
#9	AnnotatorNotes T12	C0685938; Malignant neoplasm of gastrointestinal tract; Neoplastic Process
T13	DISO 500 529	carcinomas gastrointestinales
T14	DISO 566 578	intolerantes
#10	AnnotatorNotes T14	C0277585; Intolerance to drug; Pathologic Function
T15	DISO 669 684	cáncer de colon
#11	AnnotatorNotes T15	C0007102; Malignant tumor of colon; Neoplastic Process
T16	DISO 687 707	metástasis hepáticas
#12	AnnotatorNotes T16	C0494165; Secondary malignant neoplasm of liver; Neoplastic Process
T17	DISO 734 746	intolerantes
#13	AnnotatorNotes T17	C0277585; Intolerance to drug; Pathologic Function
T18	DISO 822 839	lesión mensurable
T19	DISO 987 992	tumor
#14	AnnotatorNotes T19	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C0577559; Mass of body structure; Finding
T20	DISO 1029 1044	cáncer de colon
#15	AnnotatorNotes T20	C0007102; Malignant tumor of colon; Neoplastic Process
T21	PROC 1047 1078	Indice de filtración glomerular
T22	DISO 1152 1172	Enfermedades Renales
#16	AnnotatorNotes T22	C0022658; Kidney Diseases; Disease or Syndrome
T23	DISO 1183 1200	Inmunodeficiencia
#17	AnnotatorNotes T23	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome
T24	DISO 1214 1224	enfermedad
#18	AnnotatorNotes T24	C0012634; Disease; Disease or Syndrome
T25	DISO 1254 1258	SIDA
#19	AnnotatorNotes T25	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T26	CHEM 1264 1285	agente inmunosupresor
#20	AnnotatorNotes T26	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T27	CHEM 1299 1316	corticoesteroides
#21	AnnotatorNotes T27	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T28	CHEM 1370 1382	prednisolona
#22	AnnotatorNotes T28	C0032950; prednisolone; Organic Chemical · Pharmacologic Substance
T29	PROC 1459 1470	tratamiento
#23	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	ANAT 1510 1517	cutánea
#24	AnnotatorNotes T30	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T31	DISO 1553 1559	eccema
#25	AnnotatorNotes T31	C0013595; Eczema; Disease or Syndrome
T32	DISO 1565 1583	dermatitis atópica
#26	AnnotatorNotes T32	C0011615; Dermatitis, Atopic; Disease or Syndrome
T33	PROC 1598 1619	tratamiento sistémico
T34	PROC 1687 1698	tratamiento
#27	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	CHEM 66 72	TG6002
T36	CHEM 188 194	TG6002
T37	CHEM 319 323	5-FC
T38	ANAT 679 684	colon
#28	AnnotatorNotes T38	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T39	ANAT 698 707	hepáticas
#29	AnnotatorNotes T39	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T40	ANAT 1039 1044	colon
#30	AnnotatorNotes T40	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T41	PROC 1113 1148	fórmula de Modificación de la Dieta
T42	ANAT 1165 1172	Renales
#31	AnnotatorNotes T42	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T43	DISO 1250 1253	VIH
#32	AnnotatorNotes T43	C0458074; Human immunodeficiency virus (HIV) status; Finding
T44	DISO 1501 1529	afeccion cutánea exfoliativa
#33	AnnotatorNotes T44	C0241088; SKIN LESION EXFOLIATION; Finding
T45	CHEM 1703 1709	TG6002
T46	CHEM 1475 1481	TG6002
T47	ANAT 511 529	gastrointestinales
#34	AnnotatorNotes T47	C0012240; Gastrointestinal system; Body System
T48	PROC 964 975	Irradiación
#35	AnnotatorNotes T48	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T49	DISO 1010 1014	dMMR
T50	PROC 1174 1178	MDRD
#36	AnnotatorNotes T50	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
T51	DISO 1001 1009	MSI-Alto
T52	Date 13 17	2018
T53	LIVB 90 99	pacientes
#37	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Route 244 256	intravenosas
#38	AnnotatorNotes T54	C1522726; Intravenous Route of Drug Administration; Functional Concept
T55	Route 258 262	i.v.
#39	AnnotatorNotes T55	C1522726; Intravenous Route of Drug Administration; Functional Concept
T56	Route 295 299	oral
#40	AnnotatorNotes T56	C1527415; Oral Route of Drug administration; Functional Concept
T57	LIVB 328 337	pacientes
#41	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T59	LIVB 486 495	pacientes
#42	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T61	LIVB 655 664	pacientes
#43	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 787 795	Paciente
#44	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T64	LIVB 1015 1024	pacientes
#45	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T68	Dose 1331 1347	una dosis >10 mg
T69	Frequency 1347 1351	/día
T70	Duration 1399 1415	más de 4 semanas
T71	Duration 1426 1437	los 3 meses
T72	Duration 1628 1644	más de 4 semanas
T73	Duration 1655 1665	los 2 años
T74	LIVB 452 474	Población de pacientes
#46	AnnotatorNotes T74	C1257890; Population; Population Group + C0030705; Patients; Patient or Disabled Group
T75	LIVB 619 641	Población de pacientes
#47	AnnotatorNotes T75	C1257890; Population; Population Group + C0030705; Patients; Patient or Disabled Group
T58	PHYS 1057 1078	filtración glomerular
#48	AnnotatorNotes T58	C0232809; Glomerular filtration; Organ or Tissue Function
T60	PROC 911 927	Estado funcional
#49	AnnotatorNotes T60	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T63	ANAT 1068 1078	glomerular
#50	AnnotatorNotes T63	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
A1	Status T48 History_of
A2	Status T44 History_of
A3	Status T31 History_of
A4	Status T32 History_of
#51	AnnotatorNotes T5	C1519043; Phase I/II Trial; Research Activity
#52	AnnotatorNotes T13	C0685938; Malignant neoplasm of gastrointestinal tract; Neoplastic Process
#53	AnnotatorNotes T18	C5238366; Measurable Lesion; Finding 
#54	AnnotatorNotes T51	C4523846; MSI-high; Neoplastic Process 
#55	AnnotatorNotes T21	C0017654; Glomerular Filtration Rate; Diagnostic procedure
#56	AnnotatorNotes T37	C0016278; flucytosine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
R1	Experiences Arg1:T53 Arg2:T35	
R3	Experiences Arg1:T53 Arg2:T3	
R4	Location_of Arg1:T4 Arg2:T3	
#57	AnnotatorNotes T10	C4524926; Metastatic Digestive System Carcinoma; Neoplastic Process 
R5	Location_of Arg1:T11 Arg2:T10	
#58	AnnotatorNotes T3	C4524926; Metastatic Digestive System Carcinoma; Neoplastic Process
R6	Used_for Arg1:T36 Arg2:T6	
R7	Has_Route_or_Mode Arg1:T36 Arg2:T54	
R8	Has_Route_or_Mode Arg1:T36 Arg2:T55	
R9	Combined_with Arg1:T36 Arg2:T8	
R2	Combined_with Arg1:T35 Arg2:T2	
R10	Has_Route_or_Mode Arg1:T8 Arg2:T56	
R11	Has_Route_or_Mode Arg1:T9 Arg2:T56	
R12	Has_Route_or_Mode Arg1:T37 Arg2:T56	
R13	Combined_with Arg1:T36 Arg2:T9	
R14	Combined_with Arg1:T36 Arg2:T37	
R15	Experiences Arg1:T57 Arg2:T36	
R16	Experiences Arg1:T57 Arg2:T6	
R17	Experiences Arg1:T57 Arg2:T8	
R18	Experiences Arg1:T57 Arg2:T9	
R19	Experiences Arg1:T57 Arg2:T10	
R20	Location_of Arg1:T7 Arg2:T12	
R21	Location_of Arg1:T47 Arg2:T13	
T65	Quantifier_or_Qualifier 530 539	avanzados
#59	AnnotatorNotes T65	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R22	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T65	
R23	Experiences Arg1:T59 Arg2:T13	
R24	Experiences Arg1:T74 Arg2:T13	
R25	Experiences Arg1:T74 Arg2:T14	
R26	Experiences Arg1:T59 Arg2:T14	
T66	Observation 548 557	fracasado
#60	AnnotatorNotes T66	C0162643; treatment failure; Finding
R27	Experiences Arg1:T74 Arg2:T66	
R28	Experiences Arg1:T59 Arg2:T66	
R29	Before Arg1:T13 Arg2:T66	
R30	Before Arg1:T13 Arg2:T14	
R31	Location_of Arg1:T38 Arg2:T15	
R32	Location_of Arg1:T39 Arg2:T16	
R33	Experiences Arg1:T75 Arg2:T15	
R34	Experiences Arg1:T75 Arg2:T16	
R35	Experiences Arg1:T75 Arg2:T17	
R36	Experiences Arg1:T61 Arg2:T15	
R37	Experiences Arg1:T61 Arg2:T16	
R38	Experiences Arg1:T61 Arg2:T17	
T67	Observation 716 725	fracasado
#61	AnnotatorNotes T67	C0162643; treatment failure; Finding
R39	Experiences Arg1:T75 Arg2:T67	
R40	Before Arg1:T15 Arg2:T67	
R41	Before Arg1:T16 Arg2:T17	
R42	Before Arg1:T16 Arg2:T67	
R43	Before Arg1:T15 Arg2:T17	
T76	Quantifier_or_Qualifier 809 821	al menos una
R44	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T76	
T77	CONC 846 856	RECIST 1.1
#62	AnnotatorNotes T77	C4086827; Response Evaluation Criteria in Solid Tumors Version 1.1; Intellectual Product
R45	Experiences Arg1:T62 Arg2:T18	
T78	CONC 863 871	fase IIa
R46	Overlap Arg1:T18 Arg2:T78	
T79	CONC 928 932	ECOG
#63	AnnotatorNotes T79	C1520224; ECOG performance status; Intellectual Product
R47	Used_for Arg1:T79 Arg2:T60	
T80	Result_or_Value 933 938	0 o 1
R48	Has_Result_or_Value Arg1:T79 Arg2:T80	
T81	Quantifier_or_Qualifier 993 998	diana
#64	AnnotatorNotes T81	C1521840; Target; Functional Concept
R49	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T81	
R50	Location_of Arg1:T40 Arg2:T20	
R51	Experiences Arg1:T64 Arg2:T51	
R52	Experiences Arg1:T64 Arg2:T49	
R53	Experiences Arg1:T64 Arg2:T20	
#65	AnnotatorNotes T49	C4522088; Mismatch Repair Deficiency; Finding
R54	Overlap Arg1:T51 Arg2:T20	
R55	Overlap Arg1:T49 Arg2:T20	
R56	Location_of Arg1:T63 Arg2:T58	
R57	Location_of Arg1:T63 Arg2:T21	
T82	Result_or_Value 1079 1096	<60 ml/min/1.73m2
R58	Has_Result_or_Value Arg1:T21 Arg2:T82	
R60	Location_of Arg1:T42 Arg2:T22	
#66	AnnotatorNotes T41	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
R62	Causes Arg1:T24 Arg2:T23	
R63	Causes Arg1:T43 Arg2:T23	
R64	Causes Arg1:T25 Arg2:T23	
R65	Causes Arg1:T26 Arg2:T23	
R66	Causes Arg1:T27 Arg2:T23	
R67	Has_Dose_or_Strength Arg1:T27 Arg2:T68	
R68	Has_Frequency Arg1:T27 Arg2:T69	
T83	Route 1317 1327	sistémicos
#67	AnnotatorNotes T83	C0205373; Systemic; Functional Concept
R69	Has_Route_or_Mode Arg1:T27 Arg2:T83	
T84	CONC 1355 1382	equivalentes a prednisolona
R70	Has_Duration_or_Interval Arg1:T27 Arg2:T70	
R71	Overlap Arg1:T27 Arg2:T71	
R72	Before Arg1:T27 Arg2:T29	
R73	Used_for Arg1:T46 Arg2:T29	
R74	Location_of Arg1:T30 Arg2:T44	
T85	Quantifier_or_Qualifier 1530 1535	grava
#68	AnnotatorNotes T85	C1547227; Severe - Severity of Illness Code; Intellectual Product
R75	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T85	
R76	Location_of Arg1:T30 Arg2:T31	
R77	Location_of Arg1:T30 Arg2:T32	
R78	Has_Duration_or_Interval Arg1:T33 Arg2:T72	
R79	Overlap Arg1:T33 Arg2:T73	
R80	Before Arg1:T33 Arg2:T34	
R81	Used_for Arg1:T45 Arg2:T34	
#69	AnnotatorNotes T33	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R59	Experiences Arg1:T57 Arg2:T37	
T86	Route 1610 1619	sistémico
#70	AnnotatorNotes T86	C0205373; Systemic; Functional Concept
R61	Has_Route_or_Mode Arg1:T33 Arg2:T86	
A5	Experiencer T53 Patient
A6	Experiencer T57 Patient
A7	Experiencer T74 Patient
A8	Experiencer T59 Patient
A9	Experiencer T75 Patient
A10	Experiencer T61 Patient
A11	Experiencer T62 Patient
A12	Experiencer T64 Patient
